13.07.2018
Drägerwerk AG & Co. KGaA DE0005550602
DGAP-Adhoc: Drägerwerk AG & Co. KGaA: preliminary result for the first half year
DGAP-Ad-hoc: Drägerwerk AG & Co. KGaA / Key word(s): Preliminary Results
Drägerwerk AG & Co. KGaA: preliminary result for the first half year
13-Jul-2018 / 17:33 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Based on preliminary figures, Drägerwerk AG & Co. KGaA recorded net of
currency effects a 1.4 percent (nominally -1.6 percent) increase in order
intake year-on-year in the second quarter of 2018. Net sales increased net
of currency effects by 10.1 percent (nominally 6.7 percent) to roughly EUR
620 million (Q2 2017: EUR 581.0 million). Despite the higher net sales
volume, the EBIT for the quarter stood at about EUR 3 million, significantly
below the level of the prior-year quarter (Q2 2017: EUR 16.8 million). This
was due in particular to a lower gross profit margin of roughly 43.3 percent
(Q2 2017: 44.4 percent) and higher functional expenses. In addition to
negative currency effects, higher quality costs and a negative product mix
burdened the gross profit margin.
For the first half of the year, this resulted in a year-on-year increase in
order intake of 2.0 percent net of currency effects (nominally -2.2
percent). The regions Europe and particularly Africa, Asia, and Australia
recorded higher order intake net of currency effects compared to the
prior-year period. By contrast, in the region Americas order intake was
roughly 2 percent (net of currency effects) below the level of the
prior-year. Nominally, net sales of the Dräger group stood at about EUR
1,115 million and was on par with the level of the prior-year (6 months
2017: EUR 1,116.0 million). This corresponds to a net sales growth net of
currency effects of roughly 4 percent. The gross margin was roughly 42.5
percent (6 months 2017: 44.6 percent). Compared to the prior-year period,
functional expenses increased net of currency effects by 9.5 percent
(nominally 6.7 percent) in the first half of 2017. Due to the negative
earnings in the first quarter, EBIT for the six months period stood at only
roughly EUR -37 million (6 months 2017: EUR 19.1 million), corresponding to
an EBIT margin of roughly -3.3 percent (6 months 2017: 1.7 percent).
Despite the negative earnings in the first six months, the full-year
guidance remains unchanged. For the full-year, Dräger continues to expect
net sales growth (net of currency effects) of between 2.0 and 5.0 percent
and an EBIT margin of between 4.0 and 6.0 percent. The EBIT margin is likely
to come out in the lower range of the guidance.
Dräger will publish final results for the first six months of 2018 on July
26, 2018.
Drägerwerk AG & Co. KGaA
Moislinger Allee 53-55
23558 Lübeck, Deutschland
www.draeger.com
Investor Relations:
Thomas Fischler
Tel. +49 451 882-2685
[email protected]
Corporate Communications:
Melanie Kamann
Tel. +49 451 882-3998
[email protected]
---------------------------------------------------------------------------
13-Jul-2018 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Drägerwerk AG & Co. KGaA
Moislinger Allee 53-55
23542 Lübeck
Germany
Phone: +49 (0)451 882-0
Fax: +49 (0)451 882-2080
E-mail: [email protected]
Internet: www.draeger.com
ISIN: DE0005550602, DE 000 555 063 6, DE 000 555 065 1, DE 000
555 067 7, DE 000 555 071 9
WKN: 555060, 555063 Vorzüge, 555065 Genussschein A, 555067
Genussschein K, 555071 Genussschein D
Indices: TecDAX
Listed: Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime
Standard), Hamburg, Hanover, Munich; Regulated Unofficial
Market in Stuttgart, Tradegate Exchange
End of Announcement DGAP News Service
---------------------------------------------------------------------------
704585 13-Jul-2018 CET/CEST
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Drägerwerk AG & Co. KGaA ISIN: DE0005550602 können Sie bei EQS abrufen
Medtech , 555060 , DRW8 , XETR:DRW8